Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)

• Status: Terminated
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this clinical trial was to evaluate the efficacy and tolerability of the sequential therapy of VCD/IE in the patients with ESFT.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University

Criteria

Inclusion Criteria:

• Age range 10-65 years old

• Histological confirmed ESFT

• No previous therapy

• ECOG performance status less than 2

• Life expectancy of more than 12 weeks

• Normal laboratory values: hemoglobin>8.0g/dl, neutrophil>2×109/L, platelet > 80×109/L, Hb > 80×1012/L, serum creatine < 1×upper limitation of normal(ULN), serum bilirubin < 1.5×ULN, ALT and AST < 2.5×ULN

Exclusion Criteria:

• Pregnant or lactating women

• Received treatment for the disease previously

• Serious uncontrolled diseases and intercurrent infection

• The evidence of CNS metastasis and bone marrow involvement

• History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix

• History of allergy to the drugs in this trial

• Abnormal LVEF level